Table 3 |
||||||
|
Characteristics of patients in the independent test set 1 |
||||||
|
Sample ID |
Age (years) |
Sex |
Bacterial isolation |
Antibiotherapy before blood collection |
Underlying diseases |
Survival |
|
|
||||||
|
Other sepsis (n = 11) |
||||||
|
I016* † |
61 |
Female |
Coagulase-negative staphylococci |
Ceftazidime, bactrim, Sulperazole |
Hematemesis |
Survivor |
|
I017* ठ|
50 |
Male |
Coagulase-negative staphylococci |
Ceftriaxone, ceftazidime, doxycycline, cloxacillin |
Acute pancreatitis, nephrotic syndrome |
Survivor |
|
I018§¶¥ |
57 |
Male |
Coagulase-negative staphylococci# |
Vancomycin |
T2D, CRF |
Survivor |
|
I019¤ |
58 |
Female |
Staphylococcus aureus |
Cloxacillin, ceftazidime |
T2D, wound |
Survivor |
|
I020¶¥ |
66 |
Female |
Coagulase-negative staphylococci# |
Ceftazidime, ceftriaxone |
T2D, ARF, tuberculosis |
Non-survivor |
|
I021¶ |
54 |
Female |
Enterococcus spp. |
Ceftazidime, cloxacilin |
T2D, abscess |
Non-survivor |
|
I022§¶ |
37 |
Male |
Coagulase-negative staphylococci# |
Ceftriaxone, ceftazidime |
T2D, ARF |
Non-survivor |
|
I023¶¤ |
70 |
Female |
E. coli |
Doxycycline, ceftazidime |
T2D |
Non-survivor |
|
I024¶¥ |
56 |
Male |
Coagulase-negative staphylococci |
Meropenem, ceftazidime |
T2D, RF |
Survivor |
|
I025* |
50 |
Male |
S. pneumoniae |
Ceftriaxone, meropenem |
T2D |
Non-survivor |
|
I026¶ |
57 |
Male |
K. pneumoniae |
Ceftriaxone, ceftazidime, bactrim |
T2D |
Survivor |
|
Septicemic melioidosis (n = 13) |
||||||
|
M016¶ |
39 |
Male |
B. pseudomallei |
Ceftazidime, bactrim, doxycycline |
T2D |
Survivor |
|
M017¶ |
52 |
Female |
B. pseudomallei |
Norfloxacin, ceftazolin |
T2D |
Survivor |
|
M020¶ |
61 |
Male |
B. pseudomallei |
Ceftriaxone, doxycycline, ceftazidime |
- |
Survivor |
|
M021¶ |
56 |
Female |
B. pseudomallei |
Ceftriaxone, ceftazidime |
T2D |
Survivor |
|
M022¶ |
18 |
Male |
B. pseudomallei |
Ceftazidime, cactrim |
T2D |
Survivor |
|
M023¶ |
63 |
Male |
B. pseudomallei |
Bactrim, ceftazidime |
T2D |
Survivor |
|
M024¶ |
44 |
Male |
B. pseudomallei |
Meropenem |
T2D, RF |
Survivor |
|
M025¶ |
57 |
Male |
B. pseudomallei |
Ceftazidime |
T2D |
Survivor |
|
M026¶ |
48 |
Male |
B. pseudomallei |
Ceftazidime, doxycycline, bactrim |
T2D |
Survivor |
|
M027¶ |
44 |
Male |
B. pseudomallei |
Ceftriaxone, ceftazidime, meropenem |
ARF |
Survivor |
|
M028¶ |
70 |
Male |
B. pseudomallei |
Ceftazidime, levofloxacin, bactrim |
T2D |
Survivor |
|
M029¶ |
50 |
Male |
B. pseudomallei |
Ceftriaxone, ceftazidime |
CRF |
Non-survivor |
|
M030¶ |
44 |
Male |
B. pseudomallei |
Ceftazidime, ceftriazone |
T2D, tuberculosis |
Survivor |
|
|
||||||
|
*Hospital-acquired septicemia;†long hospitalization;‡taken immunosuppressive drugs;§dialysis; ¶community-acquired septicemia; ¥mechanical ventilation; ¤wounds. #Positive by two sets of blood cultures. ARF, acute renal failure; CRF, chronic renal failure; RF, renal failure; T2D, type 2 diabetes. |
||||||
|
Pankla et al. Genome Biology 2009 10:R127 doi:10.1186/gb-2009-10-11-r127 |
||||||
